Pronóstico del mercado de enfermedades cardiometabólicas de América del Sur y Central hasta 2028: impacto de COVID-19 y análisis regional por tipo (enfermedad cardiovascular (ECV), diabetes tipo 2, hipertensión y obesidad), tratamiento (inhibidores de la ECA, diuréticos, glucófagos y otros), Dosis (tableta e inyección), vía de administración (oral e intravenosa), usuarios finales (hospitales, clínicas y entornos de atención domiciliaria) y canal de distribución (farmacia hospitalaria, farmacia minorista y farmacia en línea)
Introducción al mercado
La enfermedad cardiometabólica se caracteriza por un grupo de anomalías y síntomas que aumentan el riesgo de que las personas desarrollen enfermedades cardiovasculares. Hipertensión, obesidad, resistencia a la insulina, dislipidemia, perfil deficiente de colesterol (LDL) y tolerancia a la glucosa son algunos de los síntomas. Las personas que padecen síndrome cardiometabólico son propensas a otras enfermedades potencialmente mortales, como diabetes tipo 2, accidente cerebrovascular, enfermedad de las arterias coronarias (EAC), enfermedades cardiovasculares (CVD) y muchas otras.
Además, se espera que la creciente prevalencia de enfermedades cardiometabólicas impulse el crecimiento del mercado durante el período previsto. Sin embargo, el subdiagnóstico de las enfermedades cardiovasculares en los países de ingresos bajos y medianos (PIBM) limita el crecimiento del mercado de enfermedades cardiometabólicas de América del Sur y Central.
Brasil, Argentina, Uruguay, Chile , Perú y Colombia están preocupados por la segunda ola de infección por corona. Entre los cuales Brasil ha registrado la mayoría de las muertes. Se prevé que la región probablemente impondrá un segundo bloqueo, lo que en última instancia obstaculizará la industria de la salud en el área. Ha habido intensos intentos de explorar la terapia farmacológica para prevenir y tratar la infección por SARS-CoV-2 durante esta pandemia de COVID-19. Por lo tanto, es probable que los estudios clínicos en curso sobre el mercado de enfermedades cardiometabólicas para COVID en la región favorezcan el crecimiento del mercado.
Descripción general y dinámica del mercado
Se proyecta que el mercado de enfermedades cardiometabólicas de América del Sur y Central alcanzará los 10.295,5 millones de dólares estadounidenses para 2028 desde EE. UU. $ 8.472,6 millones en 2021; se prevé que crecerá a una tasa compuesta anual del 2,8% de 2021 a 2028. La transformación de la industria de la salud de un enfoque único para todos a un enfoque específico está ampliando la demanda de medicamentos personalizados. Debido a los avances en la medicina personalizada basada en la estructura genética individual, estos medicamentos se están convirtiendo constantemente en la marca registrada de los tratamientos de enfermedades crónicas. La creciente investigación sobre la integración del tratamiento personalizado de las enfermedades crónicas está abriendo nuevas vías terapéuticas. Los gigantes farmacéuticos también han estado explorando opciones de tratamiento personalizado para las CMD. Recientemente, Novartis recibió derechos de Akcea Therapeutics para desarrollar y comercializar TQJ230, un agente en investigación para terapia cardiovascular dirigida. Millones de personas tienen niveles elevados de lipoproteína (a), un factor de riesgo de ECV hereditario independiente que no puede abordarse eficazmente mediante la dieta y otros cambios en el estilo de vida. Si se aprueba, TQJ230 podría ser el primer tratamiento de su clase, dirigido explícitamente a la Lp(a elevada). Además, los avances en inteligencia artificial y análisis de datos están respaldando el desarrollo de la gestión de enfermedades al personalizar los medicamentos para proporcionar una intervención precisa. Estos factores han aumentado la trayectoria de crecimiento del mercado de enfermedades cardiometabólicas de América del Sur y Central.
Segmentos de mercado clave
En términos de tipo, el segmento de enfermedades cardiovasculares representó la mayor participación del mercado de enfermedades cardiometabólicas de América del Sur y Central en 2020. En términos de tratamiento, el segmento de inhibidores de la ECA representó la mayor parte mayor participación del mercado de enfermedades cardiometabólicas de América del Sur y Central en 2020. En términos de dosis, el segmento de tabletas representó la mayor participación del mercado de enfermedades cardiometabólicas de América del Sur y Central en 2020. En términos de vía de administración, el segmento oral representó para la mayor participación del mercado de enfermedades cardiometabólicas de América del Sur y Central en 2020. En términos de usuario final, el segmento hospitalario representó la mayor participación del mercado de enfermedades cardiometabólicas de América del Sur y Central en 2020. Además, según el canal de distribución, el El segmento de farmacia hospitalaria tuvo la mayor participación de mercado en 2020.
Principales fuentes y empresas incluidas
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado de enfermedades cardiometabólicas en América del Sur y Central son los sitios web de las empresas, los informes anuales, los informes financieros y los gobiernos nacionales. documentos, y base de datos estadísticos, entre otros. Las principales empresas que figuran en el informe son Bayer AG, Novartis AG, Kowa Company, Ltd., Boehringer Ingelheim International Gmbh, Novo Nordisk A/S y AstraZeneca.
Informe Razones para comprar
- Para entender el Sur y América Central, el panorama del mercado de enfermedades cardiometabólicas e identificar segmentos de mercado que probablemente garanticen un fuerte retorno
- Para comprender el panorama del mercado en constante cambio y mantenerse a la vanguardia de la competencia
- Planificar eficientemente fusiones, adquisiciones y acuerdos de asociación en el mercado de enfermedades cardiometabólicas de América del Sur y Central identificando segmentos con las ventas probables más prometedoras
- < span>Tomar decisiones comerciales informadas a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos
- Obtener un pronóstico de ingresos del mercado de enfermedades cardiometabólicas de América del Sur y Central basado en varios segmentos para el período 2021-2028
SEGMENTACIÓN DEL MERCADO DE ENFERMEDADES CARDIOMETABÓLICAS DE AMÉRICA DEL SUR Y CENTRO
Por tipo
- Enfermedad cardiovascular (ECV)
- Diabetes tipo 2
- Hipertensión
- Obesidad
- Inhibidores de la ECA
- Diuréticos
- Glucófago
- Otros
- Tableta
- Inyección
- Oral
- Intravenoso
- < span>Hospital
- Clínica
- Entornos de atención domiciliaria
- Farmacia hospitalaria
- Farmacia minorista
- Farmacia online
- América del Sur y Central
- Brasil
- Argentina
- Resto de América del Sur y Central
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
Por tratamiento
< span>Por dosis
Por Vía de Administración
Por usuarios finales
< span>Por canal de distribución
Por país
Empresas mencionadas
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 South and Central America Cardiometabolic Diseases market – By Country
2. South and Central America Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South and Central America Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. South and Central America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. South and Central America Cardiometabolic Diseases Market – Regional Analysis
6.1 South and Central America Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. South and Central America Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. South and Central America Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. South and Central America Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. South and Central America Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. South and Central America Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. South and Central America Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. South and Central America Cardiometabolic Diseases Market – Geographic Analysis
13.1 South and Central America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.3 South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.10 Brazil: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Brazil: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Brazil: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Brazil: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Brazil: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Brazil: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.15.1.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.16 Argentina: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 Argentina: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 Argentina: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 Argentina: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 Argentina: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 Argentina: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.21.1.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.22 Rest of South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 Rest of South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 Rest of South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 Rest of South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 Rest of South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 Rest of South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
14.1 South and Central America: Impact Assessment of COVID-19 Pandemic
15. South and Central America Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Kowa Company, Ltd.
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Brazil Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Brazil Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Brazil Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Brazil Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Brazil Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Brazil Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Argentina Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. Argentina Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Argentina Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Argentina Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. Argentina Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. Argentina Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. Rest of South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. Rest of South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. Rest of South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. Rest of South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Organic Developments in the Cardiometabolic Diseases Market
Table 26. Inorganic Developments in the Cardiometabolic Diseases Market
Table 27. Glossary of Terms, South and Central America Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. South and Central America Cardiometabolic Diseases Market Segmentation
Figure 2. South and Central America Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of South and Central America Cardiometabolic Diseases Market
Figure 4. South and Central America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. South and Central America Cardiometabolic Diseases Market, Industry Landscape
Figure 6. South and Central America PEST Analysis
Figure 7. South and Central America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. South and Central America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. South and Central America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. South and Central America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
Figure 40. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South and Central America cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.